• 18678 Citations
  • 63 h-Index
1987 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Marco Angelo Colleoni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 20 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
letrozole Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Tamoxifen Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1987 2019

4 Citations (Scopus)

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: Long-term follow-up of the BiG 1-98 trial

BIG 1-98 Collaborative Group and the International Breast Cancer Study Group, Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 105-114 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Disease-Free Survival
2 Citations (Scopus)

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P., Ballestrero, A., Dubsky, P., Lombard, J. M., Vuylsteke, P., Castaneda, C. A., Colleoni, M., Santos Borges, G., Ciruelos, E., Fornier, M., Boer, K., Bardia, A., Wilson, T. R., Stout, T. J. & 6 others, Hsu, J. Y., Shi, Y., Piccart, M., Gnant, M., Baselga, J. & de Azambuja, E., Sep 1 2019, In : The Lancet Oncology. 20, 9, p. 1226-1238 13 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Breast Neoplasms
Odds Ratio
1 Citation (Scopus)

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial

on behalf of the International Breast Cancer Study Group & Cancer Trials Ireland and SOLTI Group, Mar 1 2018, In : Annals of Oncology. 29, 3, p. 661-668 8 p., mdx821.

Research output: Contribution to journalArticle

Appointments and Schedules
Disease-Free Survival
Breast Neoplasms
3 Citations (Scopus)

Association of Somatic Driver Alterations with Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

Luen, S. J., Asher, R., Lee, C. K., Savas, P., Kammler, R., Dell'Orto, P., Biasi, O. M., Demanse, D., Jebailey, L., Dolan, S., Hackl, W., Thuerlimann, B., Viale, G., Colleoni, M., Regan, M. M. & Loi, S., Oct 1 2018, In : JAMA oncology. 4, 10, p. 1335-1343 9 p.

Research output: Contribution to journalArticle

Randomized Controlled Trials
Breast Neoplasms

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

International Breast Cancer Study Group Trial 23-01, Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1385-1393 9 p.

Research output: Contribution to journalArticle

Neoplasm Micrometastasis
Breast Neoplasms
Disease-Free Survival